GSK) chronic obstructive pulmonary disease (COPD) treatments, Trelegy Ellipta and Breo Ellipta. Under the Inflation Reduction Act, CMS is negotiating prices for select Medicare Part D drugs.

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

GSK) chronic obstructive pulmonary disease (COPD) treatments, Trelegy Ellipta and Breo Ellipta. Under the Inflation Reduction Act, CMS is negotiating prices for select Medicare Part D drugs. In the ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added ... solid sales growth of the asthma inhaler Trelegy Ellipta across all regions, reflecting patient ...

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

The quarter saw strong performance across key product portfolios. Flagship brands within the general medicines portfolio, including Augmentin, Ceftum, and T-Bact, strengthened their market ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...